VERTEX PHARMACEUTICALS INC / MA Quarterly Retained Earnings (Accumulated Deficit) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Retained Earnings (Accumulated Deficit) history and growth rate from Q1 2010 to Q2 2024.
  • Vertex Pharmaceuticals Inc / Ma Retained Earnings (Accumulated Deficit) for the quarter ending June 30, 2024 was $7.65B, a 6.02% decline year-over-year.
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $7.65B -$490M -6.02% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $11.2B +$4.02B +55.7% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $10.1B +$3.62B +55.5% Dec 31, 2023 10-Q 2024-08-02
Q3 2023 $9.17B +$3.47B +60.8% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $8.14B +$3.36B +70.5% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $7.22B +$3.26B +82.3% Mar 31, 2023 10-Q 2023-05-02
Q4 2022 $6.52B +$3.32B +104% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $5.7B +$3.27B +135% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $4.77B +$3.19B +202% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $3.96B +$2.45B +162% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $3.2B +$2.34B +273% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $2.43B +$2.18B +855% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $1.58B +$1.99B Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $1.51B +$2.76B Mar 31, 2021 10-Q 2021-04-30
Q4 2020 $859M +$2.71B Dec 31, 2020 10-K 2022-02-09
Q3 2020 $254M +$2.69B Sep 30, 2020 10-Q 2020-10-30
Q2 2020 -$413M +$2.08B +83.4% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 -$1.25B +$1.51B +54.7% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 -$1.85B +$1.14B +38% Dec 31, 2019 10-K 2021-02-11
Q3 2019 -$2.44B +$2.1B +46.3% Sep 30, 2019 10-Q 2019-10-31
Q2 2019 -$2.49B +$2.18B +46.6% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 -$2.76B +$2.11B +43.4% Mar 31, 2019 10-Q 2019-05-01
Q4 2018 -$2.99B +$2.13B +41.6% Dec 31, 2018 10-K 2020-02-13
Q3 2018 -$4.54B +$680M +13% Sep 30, 2018 10-Q 2018-10-25
Q2 2018 -$4.67B +$449M +8.77% Jun 30, 2018 10-Q 2018-07-26
Q1 2018 -$4.88B +$259M +5.05% Mar 31, 2018 10-Q 2018-04-27
Q4 2017 -$5.12B +$254M +4.73% Dec 31, 2017 10-K 2019-02-13
Q3 2017 -$5.22B +$186M +3.45% Sep 30, 2017 10-Q 2017-10-30
Q2 2017 -$5.12B +$250M +4.67% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 -$5.14B +$168M +3.17% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 -$5.37B -$112M -2.13% Dec 31, 2016 10-K 2018-02-15
Q3 2016 -$5.41B -$219M -4.22% Sep 30, 2016 10-Q 2016-10-31
Q2 2016 -$5.37B -$275M -5.4% Jun 30, 2016 10-Q 2016-08-01
Q1 2016 -$5.3B -$399M -8.14% Mar 31, 2016 10-Q 2016-05-03
Q4 2015 -$5.26B -$556M -11.8% Dec 31, 2015 10-K 2017-02-23
Q3 2015 -$5.19B -$659M -14.6% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 -$5.09B -$734M -16.8% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 -$4.9B -$705M -16.8% Mar 31, 2015 10-Q 2015-05-04
Q4 2014 -$4.71B -$739M -18.6% Dec 31, 2014 10-K 2016-02-16
Q3 2014 -$4.53B -$518M -12.9% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 -$4.36B -$472M -12.1% Jun 30, 2014 10-Q 2014-07-31
Q1 2014 -$4.2B -$369M -9.65% Mar 31, 2014 10-Q 2014-05-05
Q4 2013 -$3.97B -$445M -12.6% Dec 31, 2013 10-K 2015-02-13
Q3 2013 -$4.01B -$565M -16.4% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 -$3.89B -$499M -14.7% Jun 30, 2013 10-Q 2013-08-02
Q1 2013 -$3.83B -$507M -15.2% Mar 31, 2013 10-Q 2013-05-08
Q4 2012 -$3.52B -$107M -3.13% Dec 31, 2012 10-K 2014-02-11
Q3 2012 -$3.45B +$128M +3.58% Sep 30, 2012 10-Q 2012-11-06
Q2 2012 -$3.39B +$406M +10.7% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 -$3.32B +$297M +8.21% Mar 31, 2012 10-Q 2012-05-10
Q4 2011 -$3.41B +$29.6M +0.86% Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$3.57B -$309M -9.48% Sep 30, 2011 10-Q 2011-11-03
Q2 2011 -$3.79B -$740M -24.2% Jun 30, 2011 10-Q 2011-08-09
Q1 2011 -$3.62B -$765M -26.8% Mar 31, 2011 10-Q 2011-05-06
Q4 2010 -$3.44B Dec 31, 2010 10-K 2012-02-22
Q3 2010 -$3.26B Sep 30, 2010 10-Q 2010-10-28
Q2 2010 -$3.06B Jun 30, 2010 10-Q 2010-08-03
Q1 2010 -$2.86B Mar 31, 2010 10-Q 2010-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.